Cetuximab

Source: Wikipedia, the free encyclopedia.
Cetuximab
EGF receptor
Clinical data
Trade namesErbitux
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: D
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life114 hrs
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC6484H10042N1732O2023S36
Molar mass145781.92 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Cetuximab, sold under the brand name Erbitux, is an

monoclonal antibody given by intravenous infusion.[2]

In July 2009, the U.S. Food and Drug Administration (FDA) approved cetuximab (Erbitux) for treatment of colon cancer with wild-type KRAS, since it had little or no effect in colorectal tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab).[4] This was the first genetic test to guide treatment of cancer.[5] In July 2012, the FDA approved a real time PCR companion diagnostic test for KRAS, the therascreen KRAS test.[6]

Medical uses

In the US, cetuximab is

indicated for treatment of head and neck cancer and colorectal cancer.[2]

In the EU, cetuximab is indicated for the treatment of epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer and for the treatment of squamous cell cancer of the head and neck.[3]

A diagnostic immunohistochemistry assay (EGFR pharmDx) can be used to detect EGFR expression in the tumor material. Approximately 75% of patients with metastatic colorectal cancer have an EGFR-expressing tumor and are therefore considered eligible for treatment with cetuximab or panitumumab, according to FDA guidelines. Unfortunately, there is evidence that immunohistochemical EGFR receptor testing does not predict response to either cetuximab or panitumumab, so that this has been called a "misleading biomarker" that has nevertheless caused insurers and even health systems to deny payment for EGFR antibody treatment for patients who lack a positive tumor EGFR histochemical test.[5]

Head and neck cancer

Cetuximab was approved by the US

squamous cell carcinoma of the head and neck (SCCHN) or as a single agent in patients who have had prior platinum-based therapy.[7] The IMCL-9815 Phase III Registration Trial, the addition of cetuximab to radiotherapy improved clinical outcomes regardless of p16 or HPV status versus radiotherapy alone.[8] However, subsequent studies[9] and clinical trials (NRG Oncology RTOG 1016[10] and De-ESCALaTE HPV[11]) suggested cetuximab was significantly inferior in overall and progression-free survival, when compared with cisplatin
.

Side effects

One of the more serious side effects of cetuximab therapy is the incidence of

acne-like rash. This rash rarely leads to dose reductions or termination of therapy. It is generally reversible.[12]

Further severe infusion reactions include but are not limited to: fevers, chills,

hypomagnesemia due to magnesium wasting, and less commonly pulmonary and cardiac toxicity.[13]

Alpha-gal allergy

Certain geographic regions have a high rate of anaphylactic reactions to cetuximab upon the first exposure to the medication. This is unusual because exposure to the allergen must occur before the development of an allergy. Fewer than 1% of people in the northeast United States reacted, while greater than 20% in the southeast did.[14][15]

Mechanism of action

Cetuximab is a chimeric (mouse/human) monoclonal antibody which binds to and inhibits EGFR.[15]

KRAS Testing

The KRAS gene encodes a small G protein on the EGFR pathway. Cetuximab and other EGFR inhibitors only work on tumors in which KRAS is not mutated.[16][17]

In July 2009, the US Food and Drug Administration (FDA) updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab (Vectibix) and cetuximab (Erbitux)) indicated for treatment of metastatic colorectal cancer to include information about KRAS mutations.[4]

Studies have indicated that detection of KRAS gene mutations helps physicians identify patients that are unlikely to respond to treatment with targeted EGFR inhibitors, including cetuximab and panitumumab. Accordingly, genetic testing to confirm the absence of KRAS mutations (and so the presence of the KRAS wild-type gene), is now clinically routine before the start of treatment with EGFR inhibitors. mCRC patients with wild-type KRAS tumors have been shown to benefit from a response rate of over 60% and a decreased risk for progression of over 40% when treated with Erbitux as 1st-line therapy.[medical citation needed] Around 65% of mCRC patients have the KRAS wild-type gene.[medical citation needed]

There is some evidence that colorectal tumors with the KRAS G13D mutation (glycine to aspartate at codon 13) respond to EGFR inhibition (specifically, with Cetuximab).[18] While the mechanism is still under investigation, current findings suggest that susceptibility to EGFR-inhibition is due to how this particular variant maintains interactions with the GTPase activating protein (GAP) NFI.[19][20]

History

Observations on EGFR inhibition were published in 1988.

Rhone-Poulenc-Rorer.[24] The court ruled that Yeda is sole owner of the patent in the U.S., while Yeda and Sanofi-Aventis co-own the patent's foreign counterparts.[25][26][27]

Society and culture

Manufacture

  • Eli Lilly and Company is responsible for the manufacture and supply of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the U.S. and Canada.
  • Merck KGaA manufactures Erbitux for supply in its territory (outside the U.S. and Canada) as well as for Japan.[28]

Distribution

Economics

Cetuximab is given by intravenous therapy and costs up to $30,000 for eight weeks of treatment per patient.[29]

Merck KGaA had 887 million euros ($1.15 billion) in Erbitux sales in 2012, from head and neck as well as bowel cancer, while Bristol-Myers Squibb generated $702 million in sales from the drug.[30]

Erbitux was the eighth best-selling cancer drug of 2013, with sales of $1.87 billion.[31]

Biosimilars

See also:
Biosimilars

Erbitux had 2013 worldwide sales of US$1.9 billion making it a lucrative target for biosimilars developers. Additionally the patent protection for Erbitux in Europe expired in June 2014, and in the U.S. and in Japan the protection will expire in 2016.[32] However biosimilars of Erbitux are not expected until 2018.[33]

As of 2014, biosimilars of cetuximab were in development by several companies.[34][35]

Insider trading

Main article: ImClone stock trading case

Cetuximab failed to get FDA approval in 2001, which caused the stock price of the developer

Merrill Lynch, Peter Bacanovic.[36][37]

Research

The efficacy of cetuximab was explored in a clinical trial of advanced

gastric cancer published in 2013; cetuximab showed no survival benefit.[38]

A 2020 phase III multicenter randomized controlled trial headed by University College London showed that adding cetuximab to perioperative chemotherapy worsened survival for colorectal cancer patients with operable liver metastases. With over 5 years of follow-up, median overall survival (OS) dropped from 81 months for patients treated with chemotherapy alone before and after liver resection, to 55.4 months for those that also received cetuximab.[39]

A multicenter, single arm, phase II study is being conducted that is designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma.[40]

References

  1. FDA
    . Retrieved 22 Oct 2023.
  2. ^ a b c d "Erbitux- cetuximab solution". DailyMed. 27 September 2021. Retrieved 2 June 2022.
  3. ^ a b "Erbitux EPAR". European Medicines Agency. 17 September 2018. Retrieved 2 June 2022.
  4. ^ a b "Class Labeling Changes to anti-EGFR monoclonal antibodies, cetuximab (Erbitux) and panitumumab (Vectibix): KRAS Mutations". U.S. Food and Drug Administration (FDA). 2010-01-11.
  5. ^
    PMID 18946069
    .
  6. ^ "Therascreen KRAS RGQ PCR Kit – P110030". Device Approvals and Clearances. U.S. Food and Drug Administration (FDA). 2012-07-06.
  7. ^ "Cetuximab Beneficial in Head and Neck Cancer". Cancer.gov National Cancer Institute. Archived from the original on 2010-12-21. Retrieved 2013-04-13.
  8. PMID 26712222
    .
  9. PMID 32775042
    .
  10. PMID 30449625
    .
  11. PMID 30449623
    .
  12. S2CID 2618247
    .
  13. ^ 8. Micromedex Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically
  14. PMID 24468247
    .
  15. ^
    PMID 18337601
    .
  16. PMID 19339720
    .
  17. PMID 22446022
    .
  18. PMID 20978259
    .
  19. PMID 31551296
    .
  20. PMID 31611389
    .
  21. PMID 3193478
    .
  22. ^ "Yeda Research and Development Company Ltd". Archived from the original on 2016-12-04. Retrieved 2013-01-05. Technology Transfer Company of the Weizmann Institute of Science
  23. ^ Groombridge N, Gearing BP (February 2008). "Practical lessons from a "made for TV" patent litigation: The trial of Yeda Research & Development Co. Ltd. v. ImClone Systems Inc. and Aventis Pharmaceuticals Inc" (PDF). The Federal Lawyer: 51–55. Archived from the original (PDF) on 2009-09-03.
  24. ^ US patent 6217866, Sela M, Pirak E, Hurwitz E, "Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same", published 2001-04-17, assigned to Yeda Research & Development 
  25. ^ "Court ruling on Yeda vs Aventis/Imclone case" (PDF). Archived from the original (PDF) on 2011-09-27. Retrieved 2012-05-25.
  26. ^ "Yeda Research v. Imclone Systems, et al". Archived from the original on 2015-11-20. Retrieved 2015-08-30.
  27. ^ "ImClone goes up against patent dispute". USA Today. 2006-09-14.
  28. ^ a b Eli Lilly and Company Form 10-K Annual Report 2013
  29. PMID 15269308
    .
  30. ^ "Merck KGaA's Erbitux beats Avastin in bowel cancer trial, Reuters, Jun 1 2013". Archived from the original on 2016-03-06. Retrieved 2021-07-06.
  31. ^ Top 10 best-selling cancer drugs of 2013; May 29, 2014
  32. ^ Bristol-Myers Squibb Company 2013 Form 10-K
  33. ^ Merck Serono Investor & Analyst Day 2014 – Belen Garijo's presentation – Slide 41. 18 Sept 2014
  34. ^ Generics and Biosimilars Initiative (GaBI) – Biosimilars of cetuximab – 14/08/2014
  35. ^ Torrent Pharma, Reliance Life sign licensing agreement for biosimilars
  36. ^ "MARTHA STEWART'S SENTENCE: THE OVERVIEW; 5 Months in Jail, and Stewart Vows, 'I'll Be Back'". The New York Times. 17 July 2004. Retrieved 2 June 2022.
  37. ^ Bennett C (19 August 2008). "'HALF' LIFE OF MARTHA CONVICT". New York Post. Retrieved 2 June 2022.
  38. PMID 26880889
    .
  39. PMID 32014119
    .
  40. ^ "Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma". U.S. National Institutes of Health. June 2022.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Cetuximab&oldid=1214728622"